Welcome to our dedicated page for Clarivate news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate stock.
Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate (CLVT) has launched a cash tender offer for up to $75,000,000 aggregate principal amount of its subsidiary Clarivate Science Holdings Corporation's 3.875% Senior Secured Notes due 2028.
The notes have $825,000,000 aggregate principal outstanding and are identified by specified 144A and Reg S CUSIP/ISINs. The Total Consideration per $1,000 principal amount will be set using a fixed spread of 50 basis points over the yield of the 4.125% U.S. Treasury due June 30, 2028, as quoted at 2:00 p.m. New York City time on September 23, 2026, the Price Determination Date. The offer expires at 5:00 p.m. New York City time on September 23, 2026, with settlement expected on September 25, 2026, and includes payment of accrued and unpaid interest on accepted notes.
Clarivate (CLVT) has named 22 researchers as Citation Laureates 2026, recognizing Nobel-class scientific and economic discoveries across physiology or medicine, physics, chemistry and economics.
The honorees include pioneers behind GLP-1 biology and medicines for diabetes and obesity, optical coherence tomography, precision gene editing, advanced OLED technologies, and the economics of the digital economy and monetary policy. They are affiliated with institutions in seven countries/regions, with 16 based in the United States. Since 2002, 89 past Citation Laureates have later received Nobel Prizes. Candidates are drawn from the fewer than 0.02% of Web of Science papers cited more than 2,000 times.
Clarivate (NYSE:CLVT) announced expanded agentic AI capabilities across its Cortellis portfolio to support life sciences organizations throughout the drug development lifecycle. The enhancements embed AI directly into existing R&D workflows to reduce manual effort, navigate complex data and enable faster, more informed scientific and strategic decisions.
According to Clarivate, new capabilities in Cortellis Drug Discovery Intelligence, OFF-X and Cortellis Competitive Intelligence help teams accelerate discovery evaluations, advance proactive safety assessment and strengthen competitive and portfolio strategy. The platform combines proprietary data, expert curation and embedded AI to transform research, safety and market analysis into actionable intelligence.
Clarivate (NYSE: CLVT) appointed Michael Easton as Executive Vice President and Chief Financial Officer, effective August 8, 2026. He succeeds Jonathan Collins, who is stepping down as CFO to pursue another opportunity.
Easton has over 25 years of finance, accounting and operations experience and most recently served as Senior Vice President and Chief Accounting Officer, overseeing Clarivate’s core financial reporting and planning functions. As CFO, he will focus on accelerating growth, improving profitability, strengthening free cash flow generation and maintaining disciplined capital allocation. Clarivate also reported its second quarter 2026 financial results in a separate release and will host a webcast at 9:30 AM Eastern Time to review them.
Clarivate (NYSE: CLVT) reported second quarter 2026 revenues of $587.3 million, down 5.5% year over year, with organic revenues declining 1.5% as 0.7% organic subscription growth was offset by weaker transactional activity. Net loss widened to $268.6 million ($0.42/share), primarily due to a $221.7 million non-cash goodwill impairment.
Adjusted net income was $123.1 million and Adjusted EBITDA $247.2 million. For the first half, revenue was $1.17 billion, Adjusted EBITDA $488.4 million, and free cash flow $122.9 million. Total debt fell by $218.4 million to $4.25 billion. Clarivate highlighted progress on its Value Creation Plan, the previously announced Life Sciences & Healthcare divestiture, and reaffirmed its 2026 outlook, including revenue of $2.30–$2.42 billion and Adjusted EBITDA of $980 million–$1.04 billion.
Clarivate (NYSE: CLVT) announced that its AI-powered trademark risk assessment solution RiskMark has won the 2026 CODiE Award for Best AI Tool for Lawyers. Launched in 2025, RiskMark uses predictive and generative AI on 172.5 million trademark records and over five million decisions to help legal professionals evaluate trademark confusion and risk quickly and reliably.
Clarivate (NYSE: CLVT) is providing AI-assisted image search technology to power a new image search capability in the U.S. Patent and Trademark Office’s TM Search trademark system. Users can now upload images and compare them against the U.S. trademark register to help identify visually similar existing marks, improving search efficiency and result quality.
Clarivate (NYSE:CLVT) announced that France’s Bibliographic Agency for Higher Education (Abes) has selected it, under a multi-year agreement, to modernize the national academic library system using a shared, cloud-based platform built on Alma, Primo and Rapido.
The solution will unify library services, resource sharing and AI-powered discovery, replacing legacy systems for the national union catalog and interlibrary loans across a network of 3,000 libraries and over 15 million bibliographic records. Abes cited pragmatic reasons, value for money and improved service quality in a constrained economic context. The deal adds to Clarivate’s existing support for more than 70 French academic institutions.
Clarivate (NYSE: CLVT) will report its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. The earnings press release and supplement will be posted on the Clarivate investor website, followed by a conference call and webcast at 9:30 AM Eastern Time.
Clarivate (NYSE: CLVT) agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million, refocusing on its Academia & Government and Intellectual Property businesses. The company plans to use cash proceeds to reduce debt and reaffirmed its full-year 2026 outlook, including LS&H as discontinued operations.
Consideration includes $500M cash at closing, $25M deferred, and a $75M seller note. Clarivate expects a $225–$250M non-cash goodwill impairment on LS&H that will not affect its 2026 outlook metrics.